News
03 May 2018

UICC and Pfizer announce four SPARC awardees selected to take their projects to the next level

The University of Nigeria Teaching Hospital, FEMAMA and Instituto Oncoguia from Brazil, and Fundación Cima in Mexico, will receive a total amount of USD 20,000 to continue addressing the needs of metastatic breast cancer patients

Header Paragraph

The Union for International Cancer Control (UICC) and Pfizer Oncology are proud to announce the names of the four cancer organisations selected to receive additional funding for their SPARC projects, addressing the needs of metastatic breast cancer (MBC) patients. This funding was committed by Pfizer Oncology in 2017 as part of the second phase of SPARC.

The organisations are:

These projects were selected by a panel of experts on the basis of excellence, and aim to improve the quality of life of MBC patients in their own settings through the development of a patient navigation system in Nigeria, running an advocacy campaign for lawmakers in Brazil, conducting a study on patients needs in Brazil, and strengthening patients care through an online platform for patients in Mexico.

"The top-up grant will allow the birth of the first MBC horizontal community, targeting its very specific needs, as well as a source for open data analysis" said Alejandra de Cima, founder and president of Fundación Cima.

Indeed, these four top-up awardees will be able to continue their projects in parallel to the 20 organisations from 19 countries granted with a SPARC award in 2017.

The Seeding Progress and Resources for the Cancer Community (SPARC) Metastatic Breast Cancer Challenge grants, is a first-of-its-kind initiative aimed at empowering advocacy groups, hospital networks, support groups and other organisations worldwide as they initiate projects to close the gap in information, support, awareness, and policy between metastatic breast cancer and early breast cancer, as well as helping to reduce the number of women diagnosed at the metastatic stage of breast cancer.

Last update

Friday 24 March 2023

Share this page